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Abstract  
BACKGROUND: Calcification of the arteries of the lower extremities is a very common pathological process, 
which has an independent significance in the development of cardiovascular diseases. There is evidence that 
development of calcification of the arteries correlates with a mutation of the MGP protein gene representing by the 
Thr83Ala polymorphism.  
AIM: The purpose of the study was to analyse the connection of Thr83Ala polymorphism of the MGP gene with 
the development of calcification of the arteries of the lower extremities. 
METHODS: The study involved 80 patients. Half of them had signs of calcification of the arteries of the lower 
extremities. The allelic Thr83Ala polymorphism of the MGP protein gene was determined by polymerase chain 
reaction, establishing the presence of calcification of the arteries by radiological and dopplerographic methods.  
RESULTS: The study aimed to analyse the association of the Thr83Ala polymorphism of the matrix Gla protein 
gene with the development of calcification of the arteries of the lower extremities. The data obtained suggest that 
the replacement of threonine by alanine in the 83rd position of the MGP molecule can affect the functional 
properties of the protein and in particular its anticarcinogenic properties. Although there was no difference in the 
distribution of different variants of the genotype by Thr83Ala to the MGP gene polymorphism in patients with CA 
and healthy patients, but in the distribution of genotypes in the comparison groups separated by sex, it was found 
that in women, carriage of the Ala allele in a homozygous state is a factor, which protects the development of 
arterial calcination in the elderly and senile. 
CONCLUSION: Differences in the distribution of different variants of the genotype according to Thr83Ala to the 
polymorphism of the MGP gene between patients with CAD and healthy patients do not exceed the limits of 
statistical significance. In the distribution of genotypes in the comparison groups divided by sex, it was found that 
in women the carrier of the Ala-allele in the homozygous state is a factor that prevents the development of 
Menkeberg arteriosclerosis in the elderly and old age. 
 
 
 
 
 
Introduction 
 
Calcification of the arteries of the lower 
extremities (CA) is a risk factor for associated acute 
cardiovascular events, as well as gangrene of the 
lower extremities [1] [2] [3]. According to modern 
studies, calcification of peripheral arteries in older age 
groups is very common and ranges from 33.3% [1] to 
50.2% [4]. 
It is known that the matrix Gla protein (MGP) 
is a strong inhibitor of vascular calcification. It refers to 
representatives of the group of vitamin K-dependent 
proteins containing the residues of γ-carboxyglutamic 
acid (Gla). The very same group also comprises 
proteins, participating in blood coagulation: 
prothrombin, factors VII, IX and X, proteins C, S and 
Z. The human MGP molecule (molecular weight 
10kDa) includes 84 amino acid residues, five of which 
are represented by γ-carboxyglutamic acid (Gla) [5]. 
The newly synthesized MGP molecule consists of 103 
amino acid residues (84 is a mature protein, 19 is a 
transmembrane signal peptide) and contains, starting 
from at the N-terminus, three functional fragments: a 
transmembrane signal peptide, a probable site that 
Clinical Science  
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
1366                                                                                                                                                                                              https://www.id-press.eu/mjms/index 
 
recognizes γ-carboxylase (putative recognition site for 
γ-carboxylase), a domain, containing Gla (Gla-
containing domain) residues [6]. 
 The Formed in the cells MGP experiences 
undergo post-translational modification, which 
consists of the carboxylation of five glutamic acid 
residues (Glu) to form a γ-carboxyglutamic acid (Gla). 
This reaction is catalysed by the enzyme γ-glutamyl 
carboxylase (GGCX) and is conjugated with the 
oxidation of the reduced form of vitamin K 
(hydroquinone) to the 2,3-epoxide of vitamin K. Thus, 
without the oxidation of vitamin K, the carboxylation of 
the Glu residues of the MGP molecule cannot occur. 
In turn, an enough amount of vitamin K for the 
carboxylation reaction of MGP depends on the state 
of the reverse reaction of its reduction, which is 
carried out with the help of a vitamin K-epoxy-
reductase complex (VKRC). In addition to γ-
carboxylation, MGP can undergo other post-
translational modifications, specific proteolytic splitting 
in the C-terminal fragment of the molecule [7] [8] and 
phosphorylation of three serine residues at the N-
terminal tail [9]. The MGP gene in humans is 
represented by a single copy, which is containing in 
the short upper arm of the 12th chromosome 
(12p12.3-13.1) [6]. It encodes 84 amino acid residues 
of the mature protein and 19 residues of the 
transmembrane signal peptide. The length of the gene 
is 3900 nucleotides; it consists of 4 exons, separated 
by three large intermediate sequences (introns), 
containing for more than 80% of the total length of the 
gene. 
The single nucleotide polymorphism of 
Thr83Ala (rs4236) is such rearrangement, when in the 
4th exon of the MGP gene, and at 3748 positions, 
thymine is replaced by adenine. This leads to the fact 
that the 83rd amino acid of the MGP molecule of 
threonine is replaced by alanine. The change in the 
primary structure of protein molecules can request in 
a variety of functional disorders; in case of MGP, one 
should expect changes in these familiar protein effects 
that are associated with its anticarcinogenic 
properties. These include, for example, binding to 
calcium ions and hydroxyapatite crystals; binding to 
extracellular matrix components; interaction with the 
BMP-2 and elimination of the latter's effects; 
participation in the regulation of apoptosis [10] [11]. 
Thus, the purpose of the study was to analyse 
the connection of Thr83Ala polymorphism of the MGP 
gene with the development of calcification of the 
arteries of the lower extremities. 
 
 
Methods 
 
Eighty patients, attending Sumy Region 
Veterans Affairs, were involved in this study. Half of 
them (40 persons) had signs of calcification of the 
arteries of the lower extremities (main group), and the 
other 40 persons-had no signs (control group). 
Patients with diagnosed diabetes mellitus were not 
added to any of the study groups that allowed it 
possible to exclude the effect of this factor on the 
studied connections. The control group and the main 
group of patients did not differ according to persons of 
different sexes (P = 0.369), as per middle age (74.4 ± 
0.76 vs. 74.4 ± 0.97, P = 0.984) as well as according 
to body mass index (26 02 ± 0.22 versus 26.01 ± 
0.35, P = 0.999). The presence of SC was determined 
to base on X-ray and Doppler data [12]. 
The studies were carried out in compliance 
with the main provisions of the Council of Europe 
Convention on Human Rights and Biomedicine, as 
well as the Helsinki Declaration of the World Medical 
Association on the Ethical Principles of Scientific 
Medical Research with Human Participation (1964, 
with subsequent additions, including the 2000 
version). All patients signed informed consent to 
participate in the studies with a subsequent collection 
of venous blood for genetic analysis. 
Determination of gene polymorphism was 
performed using the polymerase chain reaction (PCR) 
method with subsequent by analysis of the length of 
the restriction fragments upon their detection using 
restriction fragment length polymorphism (RFLP). 
For genotyping, venous blood was collected 
in sterile conditions in a mono volume of 2.7 ml with 
potassium salt of ethylenediaminetetraacetic acid 
("Sarstedt", Germany), which served as an 
anticoagulant. The blood was frozen and stored at the 
temperature of -20°C. DNA was extracted from it 
using the "Izogen" kits (Russia). 
Amplification of the fragment of the gene 
containing the Thr83Ala site of polymorphism in the 
4th exon of the MGP gene was performed using a pair 
of specific primers: sense-5'-
TCAATAGGGAAGCCTGTGATG-3` and antisense-5`-
AGGGGGATACAAAATCAGGTG-3. The amplification 
program was as follows: denaturation-94°C (50 c), 
hybridisation of primers, 64.5°C (45 c), elongation-
72°C (1 min), totally 33 cycles. 
Later, 6 μl of the amplification product was 
incubated at the temperature of 37°C during 18 hours 
with 3 units of Eco477 restriction enzyme in R buffer 
of the following composition: 10mM Tris-HCl (pH 8.5), 
10 mM magnesium chloride 100 mM potassium 
chloride and 0.1 mg/ml albumin. The presence of 
adenine in the 3748 position of the MGP gene 
prevents restriction, and upon substitution of adenine 
by thymine restriction, it splits the amplified area of the 
4th exon (length-173 pairs of nitrogen bases) into two 
fragments: 127 and 46 base pairs (Figure 1). 
Amplifications of the achieved fragment of the 
MGP gene after restriction were separated in a 2.5% 
agarose gel, containing ethidium bromide. Horizontal 
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electrophoresis (0.1 A; 140 V) was performing for 20 
minutes. DNA visualisation after electrophoresis was 
performed using a transilluminator ("Biocom", Russia). 
Statistical analysis was carried out by using 
the SPSS-17 program. In this case, the reliability of 
the differences was determined by the Pearson 2-
criterion and the Students t-criterion. A value of p < 
0.05 was considered reliable. The odds ratio (OR) and 
the 95% confidence interval were calculated using the 
logistic regression method. 
 
 
Results 
 
There are three possible variants of the 
genotype for the Thr83Ala: Thr/Thr (homozygous for 
the main allele), Thr/Ala (heterozygotes) and Ala/Ala 
(homozygous for the minor allele) polymorphism 
(Figure 1). 
 
Figure 1: Results of the electrophoresis of fragments of the MGP 
gene after restriction for the detection of Thr83Ala polymorphism. 
Tracks 1, 3, 6, 11 correspond to the Thr/Thr genotype; 4, 5, 7, 8, 9, 
10, 12-Thr/Ala-genotype; 2-Ala/Ala genotype 
 
Genotyping patients with CA and patients of 
the control group for this SNP allowed establishing the 
frequency with which one can come across the certain 
variants of this gene meet and allow to compare them 
among the groups and according to gender. When 
checking the correspondence of the distribution of 
alleles to the Hardy-Weinberg law, it was established 
that the ratio of Thr and Ala alleles in both groups 
does not differ significantly from those expected 
(Table 1). 
Table 1: The frequency of allelic variants and alleles according 
to Thr83Ala polymorphism of the MGP gene in the control 
group and patients with CA 
 Control group Patients with CA 
Homozygotes Thr/Thr, n (%) 13 (32.5) 16 (40.0) 
Heterozygotes Thr/Ala, n (%) 17 (42.5) 19 (47.5) 
Homozygotes Ala/Ala, n (%) 10 (25.0) 5 (12.5) 
Thr-allele 0.54 0.64 
Ala-allele 0.46 0.36 

2
 0.84 0.03 
P > 0.05 > 0.05 
Note: n-the number of patients, 2 and P reflect the deviation in each group from the 
Hardy-Weinberg equilibrium 
 
Table 2 shows the results of the analysis of 
the frequencies of individual phenotypes according to 
the Thr83Ala polymorphism in the control group and 
patients with CA. They show that the ratio of 
homozygotes for the main allele (Thr/Thr), 
heterozygotes (Thr/Ala) and homozygotes for the 
minor allele (Ala/Ala) in patients with arteriocalcinosis 
comprises 40%, 47.5% and 12.5%, while in the 
control group the corresponding indices were 32.5%, 
42.5% and 25%. Differences in the distribution of 
different variants of the genotype between patients 
with CA and healthy patients did not exceed the 
statistical significance. 
Table 2: The Association of the Thr83Ala polymorphism of the 
MGP gene with the CA 
  Control CA Totally 
Thr/Thr N 13 16 29 
 32.5% 40.0%  
Thr/Ala N 17 19 36 
 42.5% 47.5%  
Ala/Ala n 10 5 15 
 25.0% 12.5%  
Totally n 40 40 80 
 100% 100%  

2
 = 2.088; P = 0.352 
Note. N is the number of patients. 
 
However, the analysis of the distribution of 
genotypes in sex-disaggregated comparison groups 
allowed to identify certain significant differences. In 
general, the ratio of the two variants of homozygotes 
and heterozygotes (Thr/Thr: Thr/Ala: Ala/Ala) in 
women and men did not differ in individuals with signs 
and without signs of CA (Table 3). In the first group, it 
was 40%: 55%: 5% for women and 40%: 40%: 20% 
for men, and for control group 18.8%: 50%: 31.2% for 
women (P = 0.081) and 41.7%: 37.5%: 20.8% for men 
(P = 0.986). However, it is easy to see that for this 
indicator, female representatives were significantly 
closer to the level of statistical significance than men. 
Table 3: The association of the Thr83Ala polymorphism of the 
MGP gene with CA in females and males 
Gender 
Genotype 
 
 
Control CA Totally 
 
 
 
Female 
Thr/Thr 
n 3 8 11 
 18.8% 40.0%  
Thr/Ala 
n 8 11 19 
 50.0% 55.0%  
Ala/Ala 
n 5 1 6 
 31.3% 5.0%  
Totally 
n 16 20 36 
 100% 100%  

2
 = 5.031; P = 0.081 
 
 
 
Male 
Thr/Thr 
n 10 8 18 
 41.7% 40.0%  
Thr/Ala 
n 9 8 17 
 37.5% 40.0%  
Ala/Ala 
n 5 4 9 
 20.8% 20.0%  
Totally 
n 24 20 44 
 100% 100%  

2
 = 0.029; P = 0.986 
Note: n - the number of patients. 
 
In women, the difference between patients 
with CA and patients without signs of arterio-
calcinosis was found when comparing individual 
variants of the genotype with each other. Therefore, it 
was found that the frequency of homozygotes in the 
minor allele (Ala/Ala) was significantly higher in 
control than in patients with CA (31.3% vs 5%, P = 
0.036). 
Using the method of logistic regression, it is 
shown (Table 4), that in women with the Ala/Ala 
genotype the risk of CA is 0.075 when comparing with 
homozygotes over the main allele (P = 0.044). This 
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means that elderly and senile patients homozygous 
for the Ala allele have a CA risk more than 10 times 
lower than Thr/Thr homozygotes. 
Table 4: Results of the analysis of the Thr83Ala association of 
the MGP gene polymorphism with calcification of the lower 
extremities arteries in women and men (logistic regression 
method) 
 95% CI for OR 
 Genotype CR SE WS P OR Lower Higher 
Totally Thr/Ala -0.096 0.501 0.037 0.847 0.908 0.340 2.424 
 Ala/Ala -0.901 0.663 1.847 0.174 0.406 0.111 1.490 
Women Thr/Ala -0.662 0.821 0.651 0.420 0.516 0.103 2.578 
 Ala/Ala -2.590 1.288 4.046 0.044 0.075 0.006 0.936 
Men Thr/Ala 0.105 0.679 0.024 0.877 1.111 0.294 4.205 
 Ala/Ala 0 0.822 0 1 1 0.200 5.004 
Note data on homozygous for the main allele (Thr/Thr). CR-coefficient of regression, SE-
standard error, WS-Wald statistics, P-indicator of statistical significance, OR-odds ratio, 
CI-confidence interval. 
 
Reduced risk of CA in women with the Ala/Ala 
genotype is also evident when comparing them with 
carriers of the Thr allele (Thr/Thr+Thr/Ala) and 
separately with heterozygotes (Thr/Ala). In the first 
case, the OR ratio is 0.116, and in the second case, 
0.145. However, due to an inadequate number of 
observations, the statistical significance of P did not 
reach the generally accepted level of confidence and 
amounted to 0.063 and 0.105, respectively. 
Therefore, there is a reason to state that in 
women the carriage of the Ala-allele in the 
homozygous state is a factor that prevents the 
development of arteriocalcinosis in the elderly and old 
age. 
The results of molecular genetic studies, 
obtained by us in patients with calcification of arteries 
of the lower extremities, can be compared with the 
data, obtained in the study of the connection of the 
Thr83Ala polymorphism of the MGP gene with the 
most common complications of the atherosclerotic 
process-acute coronary syndrome (ACS) and 
ischemic atherothrombotic stroke (IATS). Data for this 
comparison are taken from the work of the laboratory 
of molecular genetic studies of Sumy State University 
[2] [13] and are presented in Table 5. 
Table 5: Comparative characteristics of the distribution of 
genotypes according to Thr83Ala polymorphism of the MGP 
gene in patients with arterial calcification, ACS [2] and IATS [5], 
% 
 Genotype CA ACS IATS 
Disease 
(n = 40) 
Control 
(n = 40) 
Disease 
(n = 115) 
Control 
(110) 
Disease 
(170) 
Control 
(124) 
Thr83Ala Thr/Thr 40.0 32.5 4.,6 43.9 39.4 34.7 
Thr/Ala 47.5 42.5 43.5 45.9 48.8 53.2 
Ala/Ala 12.5 25.0 13.9 10.2 11.8 12.1 
Note: n - the number of patients. 
 
The data indicate that the percentage of 
homozygotes in the minor allele (Ala/Ala) in the 
control group for the CA was more than twice as high 
(25%) when comparing with the control groups of the 
other two studies (10.2% and 12.1%). At the same 
time, the percentage of such homozygotes in patients 
with CA (12.5%) corresponded to the above data for 
control in studies with ACS and IATS. 
Since the homozygous condition of the minor 
allele in women interferes with the development of 
CA, the assumption of the age (physiological) origin of 
arteriocalcinosis is quite attractive. Since in our work 
patients with diabetes mellitus, which is one of the 
main causes of CA, were excluded both from the main 
and control groups, the presence or absence of 
lesions of the arteries should occur due to some other 
factors. One of such factors may be a hereditary 
predisposition, including the Thr83Ala polymorphism 
of the MGP gene. According to our data, it can be 
assumed that women homozygous for the Ala-allele 
are "abnormal" or "sick on the contrary," because their 
genetic factor interferes with the physiological ageing 
of the arteries inherent in most people in the elderly 
and senile ages.  
The substitution of threonine for alanine at the 
83rd position of the MGP molecule can affect the 
functional characteristics of the protein and in 
particular its anticarcinogenic properties. The latter, as 
is known today, is extremely important for preventing 
calcification of the arteries, as evidenced by 
experiments with genetically knocked out MGP (-/-) 
mice [14] and warfarin-mediated aortic medication in 
rats [15]. 
In conclusion: (1) differences in the 
distribution of different variants of the genotype 
according to Thr83Ala to the polymorphism of the 
MGP gene between patients with CA and healthy 
patients do not exceed the limits of statistical 
significance; (2) in the distribution of genotypes in the 
comparison groups divided by gender, it was found 
that in case of women the carrier of the Ala-allele in 
the homozygous state is a factor that prevents the 
development of Menkeberg arteriosclerosis in the 
elderly and old ages. 
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